Consulting
Senior, hands-on, accountable to the work.
ServoSoft engagements are built around the kind of problems that don't
survive being handed off to junior staff: ambiguous scope, regulated
environments, and decisions that compound over years.
01 — Architecture & Strategy
Cloud Architecture for Regulated R&D
AWS reference architectures for clinical and pharmacometrics
workloads. Identity, networking, storage, and compute decisions
documented so they hold up under audit. GxP validation strategy,
21 CFR Part 11 alignment, and retrospective validation when the
paperwork didn't keep up with the build.
02 — Clinical Systems
EDC, eTMF, CTMS Integration
Vendor selection, integration architecture, and the operational
seams between systems and CROs. Particular interest in
organizations untangling legacy footprints or moving from a single
vendor stack to best-of-breed.
03 — AI & Agents
AI Agent Platforms
Production patterns for multi-agent systems on AWS — orchestration,
inter-agent messaging, evaluation, and the governance work that
makes the output usable for clinical and regulatory document
workflows. Bedrock AgentCore and Strands evaluation,
local-LLM strategies for sensitive document analysis.
04 — Advisory
IT Business Partner Engagements
Fractional or interim IT business partner work for R&D
functions — clinical, biostatistics, pharmacometrics, regulatory.
For organizations that need a senior counterpart to the science
but don't yet need the role full-time.
How it works
Most engagements start with a scoped two-to-four week assessment.
Output is a written deliverable — architecture, recommendation, plan
— that stands on its own whether or not the implementation work
continues with me.
Implementation engagements are typically retainer-based with a
defined deliverable and review cadence. I work primarily remote, with
occasional on-site time for stakeholder workshops or audit support.
ServoSoft LLC is a Florida-domiciled entity. Engagements are governed
by a standard MSA + SOW structure and can accommodate the
contracting requirements of public biopharma sponsors.
Start a conversation →